71. Teva 2015 ($1,200 million)
Israeli drugmaker Teva agreed to pay US$1.2 billion in May 2015 to end a seven-year FTC investigation into allegations that subsidiary Cephalon engaged in anti-competitive practices by preventing rivals from entering the marketplace.
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.